Randox develops, manufactures and markets diagnostic reagents and equipment for laboratory medicine, including Biochip Array Technology, clinical chemistry analyzers and reagents, quality control materials and schemes and an extensive life science portfolio. The company's clients include hospitals; clinical, research and molecular laboratories; and food testing, forensic toxicology, life sciences, and veterinary laboratories. Bosch Healthcare Solutions GmbH is a wholly owned subsidiary of Robert Bosch GmbH that develops products and services to improve people's health and quality of life.
Easy to use, Vivalytic is a comprehensive multiplex PCR platform that uses Randox's - patented Biochip Array Technology and features a broad range of test options. By supporting single-plex and low-plex testing, this platform also simplifies the process for otherwise complex laboratory test procedures.
The growing threat of global antibiotic resistance can also be addressed by Vivalytic. Depending on the complexity of the test, this intuitive point-of-care analyzer will deliver results from 30 minutes, thus allowing doctors to select the right course of therapy much faster than before. The first tests available on the Vivalytic are Randox's panels for respiratory and sexually-transmitted infections. Using the company's patented Biochip Array Technology, the Respiratory Multiplex Array simultaneously reports on 22 viral and bacterial pathogens including Bordetella pertussis and parapertussis, while the STI array enables the detection of 10 STIs from a single sample.
Dr Peter FitzGerald, MD of Randox Laboratories, says, "This is transformational for patients and doctors; never before has there been this level of accessibility to such a wealth of molecular tests. Randox molecular assays continue to evolve, keeping precise diagnostics for targeted patient therapy at the centre. With Vivalytic, there's no limit to the testing portfolio that can be made available on its universal platform, and importantly it delivers results quickly and accurately". He also said that Randox-Bosch partnership would enable quick, accurate diagnosis, improved patient care and the effective stewardship of critical medicines.